STOCK TITAN

IDEAYA Biosciences, Inc. - IDYA STOCK NEWS

Welcome to our dedicated page for IDEAYA Biosciences news (Ticker: IDYA), a resource for investors and traders seeking the latest updates and insights on IDEAYA Biosciences stock.

IDEAYA Biosciences, Inc. (NASDAQ: IDYA) is an innovative biotechnology firm concentrated on oncology. Established in 2015 and headquartered in South San Francisco and La Jolla, California, the company is dedicated to the discovery and development of precision medicine therapies for genetically defined patient groups. Their focus areas include synthetic lethality and immuno-oncology, targeting DNA damage repair mechanisms and the tumor microenvironment, respectively.

IDEAYA's pioneering approach leverages molecular diagnostics to identify and develop targeted therapeutics. The company's leading product candidate, IDE196, is a potent inhibitor of protein kinase C (PKC), aimed at treating cancers with GNAQ or GNA11 mutations. In addition, IDEAYA is advancing several clinical programs, such as the darovasertib program, which is currently in Phase 2 trials for uveal melanoma (UM) and has shown promising results in tumor shrinkage and eye preservation.

In synthetic lethality, IDEAYA's IDE397 targets methionine adenosyltransferase 2 alpha (MAT2A) in solid tumors with MTAP deletion, a condition prevalent in 15% of solid tumors. The IDE397 program includes both monotherapy and combination trials with other investigational drugs.

Financially, IDEAYA is robust with cash reserves exceeding $941.4 million as of Q1 2024, ensuring operational funding through 2028. Key investors include 5AM Ventures, Canaan Partners, and Celgene. The company has formed strategic collaborations with major pharmaceutical players like Pfizer, Amgen, Gilead Sciences, GSK, and Merck to amplify its research and clinical capabilities.

IDEAYA's scientific advisory board is composed of esteemed researchers, including a Nobel laureate and members of the National Academy of Sciences, underscoring the company's commitment to groundbreaking research.

Recent developments are promising: IDEAYA reported favorable Phase 2 trial results for IDE196 in UM, with significant tumor reduction and eye preservation rates. Additionally, a collaboration with Merck for the IDE161 program aims to tackle endometrial cancer using advanced immunotherapy combinations.

For more detailed updates and financial information, visit IDEAYA's Investor Relations page.

Rhea-AI Summary

IDEAYA Biosciences announced preliminary clinical results from a Phase 2 trial of darovasertib for neoadjuvant treatment in uveal melanoma (UM) at the ASCO 2024 Annual Meeting. The study, led by Dr. Anthony Joshua, involved 15 patients planned for enucleation, treated with darovasertib 300mg twice daily. Results showed a 67% eye preservation rate and a median tumor shrinkage of approximately 45% after six months. The treatment was generally well tolerated, with no serious drug-related adverse events reported. Additional data will be presented on June 3, 2024.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.92%
Tags
none
-
Rhea-AI Summary

IDEAYA Biosciences, Inc. reported its first-quarter 2024 financial results, highlighting progress in developing potential first-in-class clinical programs targeting various solid tumors, including GNAQ/11, MTAP-deletion, and HRD solid tumors. The company showcased positive advancements in its clinical pipeline, strategic partnerships, and a robust balance sheet with $941.4 million in cash, cash equivalents, and marketable securities as of March 31, 2024.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.79%
Tags
-
Rhea-AI Summary

IDEAYA Biosciences, Inc. (NASDAQ: IDYA) will participate in the RBC Capital Markets Global Healthcare Conference on May 14th, 2024. The event will feature a fireside chat with CEO Yujiro S. Hata. The company aims to engage with investors and showcase its precision medicine oncology initiatives.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.3%
Tags
conferences
Rhea-AI Summary
IDEAYA Biosciences granted non-qualified stock options to two newly hired employees under Nasdaq Listing Rule 5635(c)(4). The options allow the purchase of 62,800 shares at an exercise price of $38.62 per share, with a 10-year term and vesting over four years. The grant was made under the 2023 Inducement Plan exclusively for new employees, in line with Nasdaq regulations.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.42%
Tags
none
-
Rhea-AI Summary
IDEAYA Biosciences announces ASCO 2024 oral presentation for Darovasertib in neoadjuvant uveal melanoma phase 2 investigator-sponsored study. The presentation is scheduled for June 3, 2024, at 9:51 AM CDT, with abstract summary available on May 23, 2024, at 5:00 pm ET.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.13%
Tags
-
Rhea-AI Summary
IDEAYA Biosciences selects move-forward Phase 2 expansion dose for IDE397 monotherapy in MTAP-deletion squamous NSCLC based on promising clinical efficacy and adverse event profile. The company aims to address the high unmet medical need in this patient population and advance multiple rational combinations with pharma collaborators and internal pipeline.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.24%
Tags
Rhea-AI Summary
IDEAYA Biosciences, Inc. grants 70,000 non-qualified stock options to new employees under the 2023 Inducement Plan. The options have an exercise price of $43.88 per share, a 10-year term, and will vest over four years. This move aims to incentivize and retain talent within the company.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.68%
Tags
none
-
Rhea-AI Summary
IDEAYA Biosciences, Inc. (IDYA) will be participating in the Stifel Virtual Targeted Oncology Forum on April 16th, 2024. The event will feature a fireside chat with CEO Yujiro S. Hata. A live audio webcast will be available on the company's website, with replays accessible for 30 days.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.1%
Tags
conferences
-
Rhea-AI Summary
IDEAYA Biosciences collaborates with Merck to evaluate IDE161 in combination with KEYTRUDA in endometrial cancer patients. IDE161 shows promising results in Phase 1 trials for various solid tumors.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.71%
Tags
none
Rhea-AI Summary
IDEAYA Biosciences, Inc. (IDYA) announces participation in upcoming investor relations events including Leerink Partners Global Biopharma Conference and Jefferies Biotech on the Bay Summit. CEO Yujiro S. Hata will engage in discussions on targeted therapeutics and oncology advancements.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.19%
Tags
conferences

FAQ

What is the current stock price of IDEAYA Biosciences (IDYA)?

The current stock price of IDEAYA Biosciences (IDYA) is $25.61 as of December 20, 2024.

What is the market cap of IDEAYA Biosciences (IDYA)?

The market cap of IDEAYA Biosciences (IDYA) is approximately 2.1B.

What is IDEAYA Biosciences, Inc.?

IDEAYA Biosciences, Inc. is a biotechnology company focused on the discovery and development of precision medicine therapies for oncology.

What is the primary focus of IDEAYA's research?

IDEAYA focuses on synthetic lethality and immuno-oncology, targeting DNA damage repair and the tumor microenvironment for genetically defined patient populations.

What is IDEAYA's product pipeline?

IDEAYA's pipeline includes IDE196 for cancers with GNAQ or GNA11 mutations, IDE397 for MTAP-deleted tumors, and IDE161 targeting tumors with homologous recombination deficiency (HRD).

Who are IDEAYA's key investors?

Key investors include 5AM Ventures, Canaan Partners, Celgene, WuXi Healthcare Ventures, Novartis Institute of Biomedical Research, and Alexandria Real Estate.

Where is IDEAYA Biosciences located?

IDEAYA has offices in South San Francisco and La Jolla, California.

What recent collaborations has IDEAYA announced?

IDEAYA has announced collaborations with Pfizer, Amgen, Gilead Sciences, GSK, and Merck to strengthen its research and clinical capabilities.

What significant achievements has IDEAYA made recently?

Significant achievements include promising Phase 2 trial results for IDE196 in uveal melanoma and the advancement of IDE397 and IDE161 in clinical trials.

What is IDEAYA's financial outlook?

As of Q1 2024, IDEAYA had cash and marketable securities totaling $941.4 million, projected to fund operations through 2028.

Who comprises IDEAYA's scientific advisory board?

IDEAYA's scientific advisory board includes a Nobel laureate and members of the National Academy of Sciences, underscoring their commitment to top-tier research.

How can I stay updated on IDEAYA Biosciences?

You can stay updated on IDEAYA Biosciences by visiting their Investor Relations page at https://ir.ideayabio.com/.

IDEAYA Biosciences, Inc.

Nasdaq:IDYA

IDYA Rankings

IDYA Stock Data

2.14B
85.54M
1.04%
111.21%
11.64%
Biotechnology
Pharmaceutical Preparations
Link
United States of America
SOUTH SAN FRANCISCO